Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-23T13:37:56.176Z Has data issue: false hasContentIssue false
  • English
  • Français

Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants

Published online by Cambridge University Press:  08 August 2017

Christoph P. Hornik ,
Nikolas J. Onufrak ,
P. Brian Smith ,
Michael Cohen-Wolkowiez ,
Matthew M. Laughon ,
Reese H. Clark  and
Daniel Gonzalez
Christoph P. Hornik*
Affiliation:
Department of Pediatrics, Duke Clinical Research Institute, Duke University, Durham, North Carolina, United States of America
Nikolas J. Onufrak
Affiliation:
Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
P. Brian Smith
Affiliation:
Department of Pediatrics, Duke Clinical Research Institute, Duke University, Durham, North Carolina, United States of America
Michael Cohen-Wolkowiez
Affiliation:
Department of Pediatrics, Duke Clinical Research Institute, Duke University, Durham, North Carolina, United States of America
Matthew M. Laughon
Affiliation:
Department of Pediatrics, Division of Neonatology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
Reese H. Clark
Affiliation:
Pediatrix-Obstetrix Center for Research and Education, Sunrise, Florida, United States of America
Daniel Gonzalez
Affiliation:
Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
*
Correspondence to: C. P. Hornik, MD, MPH, Duke Clinical Research Institute, Box 17969, Durham, NC 27715, United States of America. Tel: 919 668 8935; Fax: 919 668 7058; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

The relationship between sildenafil dosing, exposure, and systemic hypotension in infants is incompletely understood.

Objectives

The aim of this study was to characterise the relationship between predicted sildenafil exposure and hypotension in hospitalised infants.

Methods

We extracted information on sildenafil dosing and clinical characteristics from electronic health records of 348 neonatal ICUs from 1997 to 2013, and we predicted drug exposure using a population pharmacokinetic model.

Results

We identified 232 infants receiving sildenafil at a median dose of 3.2 mg/kg/day (2.0, 6.0). The median steady-state area under the concentration–time curve over 24 hours (AUC24,SS) and maximum concentration of sildenafil (Cmax,SS,SIL) were 712 ng×hour/ml (401, 1561) and 129 ng/ml (69, 293), respectively. Systemic hypotension occurred in 9% of the cohort. In multivariable analysis, neither dosing nor exposure were associated with systemic hypotension: odds ratio=0.96 (95% confidence interval: 0.81, 1.14) for sildenafil dose; 0.87 (0.59, 1.28) for AUC24,SS; 1.19 (0.78, 1.82) for Cmax,SS,SIL.

Conclusions

We found no association between sildenafil dosing or exposure with systemic hypotension. Continued assessment of sildenafil’s safety profile in infants is warranted.

Keywords

Dosingexposuresystemic hypotensioninfantsildenafil
Type
Original Articles
Information
Cardiology in the Young , Volume 28 , Issue 1 , January 2018 , pp. 85 - 92
Check for updates
Copyright
© Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Steinhorn, RH. Pharmacotherapy for pulmonary hypertension. Pediatr Clin North Am 2012; 59: 1129–1146.Google Scholar
2. Porta, NF, Steinhorn, RH. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents. Clin Perinatol 2012; 39: 149–164.CrossRefGoogle ScholarPubMed
3. Buxton, N, Flannery, T, Wild, D, Bassi, S. Sildenafil (Viagra)-induced spontaneous intracerebral haemorrhage. Br J Neurosurg 2001; 15: 347–349.Google Scholar
4. Samada, K, Shiraishi, H, Aoyagi, J, Momoi, MY. Cerebral hemorrhage associated with sildenafil (Revatio) in an infant. Pediatr Cardiol 2009; 30: 998–999.Google Scholar
5. Baquero, H, Soliz, A, Neira, F, Venegas, ME, Sola, A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatr 2006; 117: 1077–1083.Google Scholar
6. Steinhorn, RH. Diagnosis and treatment of pulmonary hypertension in infancy. Early Hum Dev 2013; 89: 865–874.Google Scholar
7. Steinhorn, RH, Kinsella, JP, Pierce, C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009; 155: 841–847 e1.Google Scholar
8. Mourani, PM, Sontag, MK, Ivy, DD, Abman, SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009; 154: 379–384. e1-2.Google Scholar
9. Limjoco, J, Paquette, L, Ramanathan, R, Seri, I, Friedlich, P. Changes in mean arterial blood pressure during sildenafil use in neonates with meconium aspiration syndrome or sepsis. Am J Ther 2015; 22: 125–131.Google Scholar
10. Vassalos, A, Peng, E, Young, D, et al. Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: a randomised trial in children undergoing cardiac surgery. Anaesthes 2011; 66: 472–480.Google Scholar
11. Ahsman, MJ, Witjes, BC, Wildschut, ED, et al. Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Arch Dis Child Fetal Neonatal Ed 2010; 95: F109–F114.CrossRefGoogle ScholarPubMed
12. Mukherjee, A, Dombi, T, Wittke, B, Lalonde, R. Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther 2009; 85: 56–63.Google Scholar
13. Laughon, MM, Benjamin, DK Jr, Capparelli, EV, et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol 2011; 4: 643–652.CrossRefGoogle ScholarPubMed
14. Laughon, MM, Benjamin, DK Jr. Mechanisms to provide safe and effective drugs for children. Pediatr 2014; 134: e562–e563.Google Scholar
15. Spitzer, AR, Ellsbury, DL, Handler, D, Clark, RH. The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system – tools for “meaningful use” in continuous quality improvement. Clin Perinatol 2010; 37: 49–70.Google Scholar
16. Olsen, IE, Groveman, SA, Lawson, ML, Clark, RH, Zemel, BS. New intrauterine growth curves based on United States data. Pediatr 2010; 125: e214–e224.Google Scholar
17. Samiee-Zafarghandy, S, Smith, PB, van den Anker, JN. Safety of sildenafil in infants. Pediatr Crit Care Med 2014; 15: 362–368.Google Scholar
18. McLaughlin, VV, McGoon, MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417–1431.CrossRefGoogle ScholarPubMed
19. Galie, N, Ghofrani, HA, Torbicki, A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148–2157.Google Scholar
20. Shekerdemian, LS, Ravn, HB, Penny, DJ. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res 2004; 55: 413–418.Google Scholar
21. Farrow, KN, Groh, BS, Schumacker, PT, et al. Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells. Circ Res 2008; 102: 226–233.Google Scholar
22. Vargas-Origel, A, Gomez-Rodriguez, G, Aldana-Valenzuela, C, et al. The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol 2010; 27: 225–230.Google Scholar
23. Kearns, GL. Selecting the proper pediatric dose: it is more than size that matters. Clin Pharmacol Ther 2015; 98: 238–240.CrossRefGoogle ScholarPubMed
24. Holford, N. Dosing in children. Clin Pharmacol Ther 2010; 87: 367–370.Google Scholar
25. Thakkar, N, Gonzalez, D, Cohen-Wolkowiez, M, et al. An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants. J Perinatol 2016; 36: 744–747.Google Scholar
26. Barst, RJ, Beghetti, M, Pulido, T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation 2014; 129: 1914–1923.Google Scholar
27. Barst, RJ, Ivy, DD, Gaitan, G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation, 125: 324–334.Google Scholar
28. US Food and Drug Administration. Revatio (sildenafil): Drug Safety Communication-Recommendation against use in children. Retrieved April 20, 2016, from http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucsm317743.htm.Google Scholar
29. US Food and Drug Administration. Medical, statistical, and clinical pharmacology reviews of pediatric studies conducted under Section 505A and 505B of the Federal Food, Drug, and Cosmetic Act, as amended by the FDA Amendments Act of 2012 (FDASIA). Retrieved May 3, 2016, from http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM320473.pdf.Google Scholar
30. Dodgen, AL, Hill, KD. Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension. Drug Healthc Patient Saf 2015; 7: 175–183.Google Scholar
31. Kraemer, U, Wildschuth, E, Tibboel, D. “Out of the blue”-safety and efficacy of pulmonary hypertension treatment in childhood. Pediatr Crit Care Med 2014; 15: 377–378.Google Scholar
32. England, A, Wade, K, Smith, PB, Berezny, K, Laughon, M. Optimizing operational efficiencies in early phase trials: the Pediatric Trials Network experience. Contemp Clin Trials 2016; 47: 376–382.Google Scholar
Supplementary material: File

Hornik supplementary material

Table S1

Download Hornik supplementary material(File)
File 13.4 KB